COVID-19 Testing
COVID-19 Testing Solutions
A comprehensive product portfolio is essential to support the tremendous efforts of health authorities working on SARS-CoV-2 detection and COVID-19 control globally. Eurofins Technologies teams have worked diligently in close collaboration with leading research hospitals and many of Eurofins human clinical testing laboratories around the world to develop a broad range of testing methods to support healthcare providers.
ELISA Assays
We offer multiple immunoassays for antibody detection to SARS-CoV-2 with very good sensitivity and specificity. Antibodies testing provides information about past exposure to SARS-CoV-2. It may provide information about statistically reduced contagion risks of and from these persons. Coronavirus antibody tests could help identify donors of plasma from recovered patients that can be transfused into COVID-19 patients as a potential treatment and can be used for serosurveys to evaluate the percentage of the population exposed to the virus.
Key Benefits of the ELISA Assays
• Separate detection of IgG, IgA, and IgM antibodies to SARS-CoV-2 (NovaLisa® Assays)
• A valuable tool to assess the immune response of the patient during and after the infection
• Simple workflow, fast results
• Ease of use on any open ELISA automation platform
• CE-IVD marked
• Total antibody detection ELISA assay to detect all isotypes (IgG, IgM and IgA) in a single sample:
INgezim COVID 19 DR
Multiplex Real-Time PCR Assay
Direct pathogen detection via PCR is the method of choice to detect acute COVID-19 infections. PCR allows for detection a few days after infection as well as in subclinical / asymptomatic infections. The incubation period is in the median 5–6 days (and up to 14 days maximum). This is the time that passes between contact with the virus and the onset of first symptoms.
GSD NovaPrime® SARS-CoV-2 (COVID-19) RT-PCR is a Multiplex Real-Time PCR for the direct qualitative pathogen detection of the novel Coronavirus (SARS-CoV-2). Particularly in the early phase of a virus infection, the direct diagnostic of the pathogen is key.
Key Benefits of the PCR Assay
• Simultaneous detection of two target sequences
• Multiplex PCR – one reaction, RT and PCR in one step
• Approximately 2 hours turn-around-time
• Extraction/inhibition control included. Positive control included
• CE marking IVD. Will be submitted to the UD FDA for Emergency Use Authorization
Rapid Tests (Lateral Flow Devices)
The INgezim COVID 19 CROM is an immunochromatography total antibodies assay for determination of IgG, IgM and IgA antibodies to SARS-CoV-2 in blood and serum samples. This rapid test provides results in 10 minutes on past exposure to COVID-19 with high analytical sensitivity and specificity (see details on product pages).
Key Benefits
• Results in only 10 minutes
• Includes all the material needed to perform the test (test strip, lancet, pipette and diluent)
• Fingerprick blood test
• CE-IVD marked
Swabs of Environmental Surfaces
An integrated solution including RNA extraction and test kits based on real-time RT-PCR (Reverse transcription-polymerase chain reaction) for the detection of SARS-CoV-2 in swabs of environmental surfaces. Testing kits and reagents will enable organizations in diverse industries and sectors, as well as in healthcare, to help test, determine, monitor and eventually strengthen the effectiveness of sanitation measures put in place.
